Hanmi Science
Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult's bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition… Read more
Hanmi Science - Asset Resilience Ratio
Hanmi Science (008930) has an Asset Resilience Ratio of 0.06% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2024)
This chart shows how Hanmi Science's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Hanmi Science's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩803.62 Million | 0.06% |
| Total Liquid Assets | ₩803.62 Million | 0.06% |
Asset Resilience Insights
- Limited Liquidity: Hanmi Science maintains only 0.06% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hanmi Science Industry Peers by Asset Resilience Ratio
Compare Hanmi Science's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
C.Q. Pharmaceutical Holding Co Ltd
SHE:000950 |
Medical Distribution | 0.00% |
|
Shenzhen Glory Medical Co Ltd
SHE:002551 |
Medical Distribution | 10.46% |
|
Shandong Realcan Pharmaceutical Co Ltd
SHE:002589 |
Medical Distribution | -4.18% |
|
BCM Alliance Bhd
KLSE:0187 |
Medical Distribution | 17.12% |
|
Qingdao Baheal Medical INC.
SHE:301015 |
Medical Distribution | 3.50% |
|
Excelsior Medical Co Ltd
TW:4104 |
Medical Distribution | 3.70% |
|
CHC Healthcare Group
TW:4164 |
Medical Distribution | 0.46% |
|
China Meheco Co Ltd
SHG:600056 |
Medical Distribution | 0.35% |
Annual Asset Resilience Ratio for Hanmi Science (2000–2024)
The table below shows the annual Asset Resilience Ratio data for Hanmi Science.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.30% | ₩4.02 Billion | ₩1.35 Trillion | -0.27pp |
| 2023-12-31 | 0.57% | ₩6.93 Billion | ₩1.23 Trillion | +0.56pp |
| 2022-12-31 | 0.01% | ₩92.75 Million | ₩1.11 Trillion | +0.00pp |
| 2021-12-31 | 0.00% | ₩38.55 Million | ₩949.89 Billion | -0.02pp |
| 2020-12-31 | 0.02% | ₩177.73 Million | ₩923.22 Billion | -0.02pp |
| 2019-12-31 | 0.04% | ₩363.98 Million | ₩910.83 Billion | -0.54pp |
| 2017-12-31 | 0.58% | ₩5.49 Billion | ₩938.78 Billion | +0.21pp |
| 2010-12-31 | 0.38% | ₩3.89 Billion | ₩1.03 Trillion | +0.34pp |
| 2009-12-31 | 0.03% | ₩312.36 Million | ₩895.44 Billion | -0.10pp |
| 2008-12-31 | 0.14% | ₩1.15 Billion | ₩838.43 Billion | -0.13pp |
| 2007-12-31 | 0.26% | ₩1.82 Billion | ₩690.20 Billion | -0.15pp |
| 2006-12-31 | 0.42% | ₩2.18 Billion | ₩525.55 Billion | +0.30pp |
| 2005-12-31 | 0.12% | ₩478.43 Million | ₩408.94 Billion | -1.36pp |
| 2004-12-31 | 1.48% | ₩5.40 Billion | ₩364.87 Billion | -0.55pp |
| 2003-12-31 | 2.03% | ₩6.66 Billion | ₩327.82 Billion | -0.61pp |
| 2002-12-31 | 2.64% | ₩8.07 Billion | ₩305.50 Billion | -0.82pp |
| 2001-12-31 | 3.46% | ₩10.24 Billion | ₩295.82 Billion | +0.90pp |
| 2000-12-31 | 2.56% | ₩6.32 Billion | ₩247.17 Billion | -- |